Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

Your Pathology Report & Biomarkers: HER2, PD-L1, and TNM Staging

At a Glance

Your esophageal cancer pathology report guides your entire treatment plan. It reveals your accurate TNM stage, checks if your surgical margins are clear, and identifies crucial biomarkers like PD-L1 and HER2 that determine if you are a candidate for targeted therapies or immunotherapy.

Your pathology report is the most important document in your medical record. It is the “source of truth” that your oncology team uses to decide which drugs to use and whether you need more treatment after surgery. While these reports can be dense with medical jargon, they contain specific “keys” to your treatment plan [1][2].

The Alphabet of Staging: c, p, and yp

You will notice lowercase letters before your TNM stage (Tumor, Node, Metastasis). These prefixes tell you when and how the staging was determined [2]:

  • c (Clinical): Based on imaging (PET/CT) and procedures (Endoscopy/EUS) before any treatment begins. This is a “best estimate” used for initial planning [3][4].
  • p (Pathological): Based on the actual examination of the tumor and lymph nodes after they have been surgically removed. This is more definitive than clinical staging [1].
  • yp (Post-Treatment Pathological): Used for patients who received chemotherapy or radiation before surgery (neoadjuvant therapy). It measures how much of the cancer was left after that treatment [5][6].

Key Biomarkers: The “Dials” of Treatment

Biomarkers are specific proteins or genetic features in your cancer cells that act like dials, showing doctors which targeted therapies might work [7][8].

PD-L1 and the CPS Score

PD-L1 is a protein that cancer cells use to hide from your immune system. Doctors measure this using a Combined Positive Score (CPS). A higher score (often 1, 5, or 10 depending on the drug) suggests that immunotherapy (like pembrolizumab or nivolumab) is more likely to be effective [7][9].

HER2 (Mainly for Adenocarcinoma)

HER2 is a growth-promoting protein. Testing usually happens in two steps [10][11]:

  1. IHC (Immunohistochemistry): Measures how much protein is on the cell surface. Results are 0, 1+, 2+, or 3+.
  2. FISH/ISH (In Situ Hybridization): If the IHC is “equivocal” (2+), this more sensitive genetic test is done to confirm if the HER2 gene is overactive [12][13].

MSI/MMR and Claudin 18.2

  • MSI (Microsatellite Instability) / MMR (Mismatch Repair): These tests check for errors in the cell’s DNA-repair machinery. If a tumor is MSI-High or dMMR (deficient mismatch repair), it often responds exceptionally well to immunotherapy [14][8].
  • CLDN18.2 (Claudin 18.2): An emerging biomarker for Adenocarcinoma. If your tumor “expresses” this protein, new targeted drugs may be an option for you [8][15].

The Pathology Checklist

A complete esophageal pathology report should include these critical details. Use this list to verify yours is complete:

  • [ ] Histologic Type: Confirms if it is Adenocarcinoma or Squamous Cell Carcinoma [1].
  • [ ] Grade (G): How “angry” the cells look (G1 is low-grade/slow; G3 is high-grade/aggressive) [1].
  • [ ] Lymphovascular Invasion (LVI): Whether cancer cells have been found inside small blood or lymph vessels [1].
  • [ ] Margin Status: Whether the edges of the removed tissue are “clear” (Negative/R0) or if cancer cells were found at the edge (Positive/R1 or R2) [16].
  • [ ] Nodes: The number of lymph nodes removed and how many contained cancer (e.g., “0 of 15 nodes”) [2].
  • [ ] Tumor Regression Grade (TRG): Only for yp reports; it scores how well the tumor responded to pre-surgery treatment [17].

Common questions in this guide

What do the letters c, p, and yp mean in my cancer stage?
These lowercase letters tell you when and how your esophageal cancer was staged. A 'c' stands for clinical staging based on initial scans, 'p' is for pathological staging after surgery, and 'yp' is used if you had chemotherapy or radiation before surgery.
What does a PD-L1 CPS score mean for my treatment?
The Combined Positive Score (CPS) measures how much of the PD-L1 protein is present on your cancer cells. A higher score suggests that your tumor is more likely to respond well to immunotherapy drugs.
Why is HER2 testing important for esophageal adenocarcinoma?
HER2 is a growth-promoting protein found on some cancer cells. If tests like IHC or FISH show your tumor has high levels of HER2, your doctor may recommend specific targeted therapies designed to attack those cells.
What does it mean if my surgical margins are clear or negative?
Clear or negative margins mean that no cancer cells were found at the very edge of the tissue removed during surgery. This indicates that the surgeon was likely able to remove the entire tumor.
What is Tumor Regression Grade (TRG)?
Tumor Regression Grade is a score used to measure how well your esophageal cancer responded to treatments like chemotherapy or radiation given before surgery. A better score means less active cancer was found in the tissue removed during your operation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my PD-L1 Combined Positive Score (CPS), and what does that mean for my eligibility for immunotherapy?
  2. 2.Was my HER2 status determined by IHC, and if the result was 2+, did you follow up with a FISH/ISH test?
  3. 3.Given my specific cell type, have we tested for MSI/MMR status and Claudin 18.2 (CLDN18.2)?
  4. 4.In my post-treatment report, what does the 'yp' prefix indicate about how well my tumor responded to the radiation or chemotherapy?
  5. 5.What was the grade of my tumor (G1, G2, or G3), and does the report mention lymphovascular invasion (LVI)?
  6. 6.Are all my surgical margins 'clear' or 'negative,' and what is the distance of the closest margin?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Examination of Surgical Specimens of the Esophagus.

    Bejarano PA, Berho M

    Archives of pathology & laboratory medicine 2015; (139(11)):1446-54 doi:10.5858/arpa.2014-0506-RA.

    PMID: 26516942
  2. 2

    An updated review of the TNM classification system for cancer of the oesophagus and its complications.

    López Sala P, Alberdi Aldasoro N, Fuertes Fernández I, Sáenz Bañuelos J

    Radiologia 2021; (63(5)):445-455 doi:10.1016/j.rxeng.2020.09.004.

    PMID: 34625200
  3. 3

    Impact of endoscopic ultrasonography on the accuracy of T staging in esophageal cancer and factors associated with its accuracy: A retrospective study.

    Wang M, Zhu Y, Li Z, et al.

    Medicine 2022; (101(8)):e28603 doi:10.1097/MD.0000000000028603.

    PMID: 35212271
  4. 4

    FAPI-PET/CT guided radiotherapy for patients with esophageal cancer.

    Kröger K, Pepper NB, Ventura D, et al.

    Radiation oncology (London, England) 2025; (20(1)):29 doi:10.1186/s13014-025-02606-x.

    PMID: 40022163
  5. 5

    Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data.

    Rice TW, Lerut TE, Orringer MB, et al.

    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2016; (29(7)):715-723 doi:10.1111/dote.12513.

    PMID: 27731548
  6. 6

    The optimal neoadjuvant treatment of locally advanced esophageal cancer.

    van der Wilk BJ, Eyck BM, Lagarde SM, et al.

    Journal of thoracic disease 2019; (11(Suppl 5)):S621-S631 doi:10.21037/jtd.2018.11.143.

    PMID: 31080638
  7. 7

    Contemporary management of advanced gastric and gastroesophageal adenocarcinomas.

    Rogers JE, Ajani JA

    Expert review of anticancer therapy 2025; 1-7 doi:10.1080/14737140.2025.2463493.

    PMID: 39918299
  8. 8

    Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps.

    Akumaga T, Park H, Lockhart AC, Jin RU

    Drug design, development and therapy 2025; (19()):12049-12076 doi:10.2147/DDDT.S543686.

    PMID: 41502549
  9. 9

    Immunotherapy in the Management of Esophagogastric Cancer: A Practical Review.

    Patruni S, Fayyaz F, Bien J, et al.

    JCO oncology practice 2023; (19(3)):107-115 doi:10.1200/OP.22.00226.

    PMID: 36409967
  10. 10

    A survival guide to HER2 testing in gastric/gastroesophageal junction carcinoma.

    Subasinghe D, Acott N, Kumarasinghe MP

    Gastrointestinal endoscopy 2019; (90(1)):44-54 doi:10.1016/j.gie.2019.03.022.

    PMID: 30928424
  11. 11

    HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.

    Wong NACS, Amary F, Butler R, et al.

    Journal of clinical pathology 2018; (71(5)):388-394 doi:10.1136/jclinpath-2017-204943.

    PMID: 29439009
  12. 12

    HER2 Status in Gastric and Gastroesophageal Carcinomas: Evaluation of Histopathological Fingings, Paired ResectionBiopsy Specimens, and the Effect of Neoadjuvant Therapy: A Single Center Study.

    Yuzuguldu RI, Sagol O, Unlu M, et al.

    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2025; (36(6)):357-370 doi:10.5152/tjg.2025.24488.

    PMID: 39840863
  13. 13

    HER2 testing in gastric cancer: results of a German expert meeting.

    Lordick F, Al-Batran SE, Dietel M, et al.

    Journal of cancer research and clinical oncology 2017; (143(5)):835-841 doi:10.1007/s00432-017-2374-x.

    PMID: 28285403
  14. 14

    Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing.

    Lavacchi D, Fancelli S, Buttitta E, et al.

    International journal of molecular sciences 2023; (24(5)) doi:10.3390/ijms24054877.

    PMID: 36902306
  15. 15

    Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies.

    Moentenich V, Gebauer F, Comut E, et al.

    Oncology letters 2020; (19(6)):3665-3670 doi:10.3892/ol.2020.11520.

    PMID: 32391091
  16. 16

    Optimal management of gastroesophageal junction cancer.

    Greally M, Agarwal R, Ilson DH

    Cancer 2019; (125(12)):1990-2001 doi:10.1002/cncr.32066.

    PMID: 30973648
  17. 17

    Stage-directed individualized therapy in esophageal cancer.

    Goense L, van Rossum PS, Kandioler D, et al.

    Annals of the New York Academy of Sciences 2016; (1381(1)):50-65 doi:10.1111/nyas.13113.

    PMID: 27384385

This page explains esophageal cancer pathology terminology for educational purposes only. Your pathologist and oncologist are the best sources for interpreting your specific medical report.

Get notified when new evidence is published on Carcinoma of esophagus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.